Yahoo Finance

• Net Asset Value (NAV): SEK4.262 billion at the end of September, down from SEK4.379 billion at the end of June, a decrease of SEK118 million.

• NAV per Share: SEK54.59 at the end of September, compared to SEK56.10 at the end of June, a decrease of 2.7%.

• Portfolio Fair Value: SEK2.993 billion at the end of September, down from SEK3.058 billion at the end of June, a decrease of SEK65 million or 4%.

• Net Profit: Minus SEK117 million for the quarter.

• Cash Balance: SEK911 million at the end of September.

• PD Segment Fair Value: SEK2.354 billion at the end of the quarter, a decrease of SEK11 million.

• CG Segment Fair Value: SEK547 billion at the end of September, down from SEK617 billion at the beginning of the quarter, a decrease of SEK70 billion.

• Investments in PD Segment: SEK30 million in the quarter.

• Investments in CG Segment: SEK10 million in the quarter.

• Limited Partnerships Investments: SEK16 million in the quarter.

• Warning! GuruFocus has detected 3 Warning Signs with STU:1NP1.

Release Date: October 16, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Flerie AB (STU:1NP1) is optimistic about the potential market entry of Xspray's Dasynoc in the US next year, which could significantly impact their portfolio.

• The company is investing in innovative technologies, such as AnaCardio's heart failure drug and Amarna Therapeutics' gene therapy for type 1 diabetes, showcasing a strong commitment to groundbreaking medical advancements.

• Microbiotica has advanced to the clinical stage with its microbiome treatment for melanoma and ulcerative colitis, indicating progress in Flerie AB's portfolio.

• Flerie AB maintains a diversified portfolio with companies like Geneos Therapeutics and Mendes making significant progress in their respective fields, enhancing the potential for future growth.

• The company has a robust cash balance of over SEK1 billion, providing ample resources for future investments and portfolio expansion.

Negative Points

• Flerie AB's net asset value decreased by SEK118 million in the third quarter, reflecting a negative financial performance.

• The company's net profit for the quarter was a loss of SEK117 million, indicating financial challenges.

• There was a decrease in the fair value of the portfolio by SEK65 million, primarily due to value decreases in certain investments.

• Xspray, a significant part of the portfolio, experienced a decrease in value by SEK173 million, impacting the overall portfolio valuation.

• The share price of Flerie AB is trading at a 30% discount to its NAV per share, highlighting a potential lack of market confidence in the company's valuation.